Krystal Biotech, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Amount
Krystal Biotech, Inc. (KRYS) reported Effective Income Tax Rate Reconciliation, Tax Credit, Amount of $3.88 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCredits · last filed 2025-02-19
- Krystal Biotech, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2024 was $3.88M, a 13.06% decline from fiscal 2023.
- Krystal Biotech, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2023 was $4.46M, a 40.76% increase from fiscal 2022.
- Krystal Biotech, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2022 was $3.17M, a 151.55% increase from fiscal 2021.
- Krystal Biotech, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2021 was $1.26M, a 41.94% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $3.88M 10-K · filed 2025-02-19 | |
| 2023-12-31 | $4.46M 10-K · filed 2025-02-19 | |
| 2022-12-31 | $3.17M 10-K · filed 2025-02-19 | $1.74M 10-K · filed 2023-02-27 |
| 2021-12-31 | $1.26M 10-K · filed 2024-02-26 | $1.29M 10-K · filed 2022-02-28 |
| 2020-12-31 | $887.00K 10-K · filed 2023-02-27 | |
| 2019-12-31 | $604.00K 10-K · filed 2021-03-01 | |
| 2018-12-31 | $143.00K 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |